Dobutamine
Adrenergic and Dopaminergic Agents
- Drug class
- Adrenergic and Dopaminergic Agents
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 2
- Products on record
- 9
Overview
Dobutamine is an active pharmaceutical ingredient in the Adrenergic and Dopaminergic Agents group (C01CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | April 17, 2026 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
5 mg/ml concentrate for solution for infusion is indicated in adults who require inotropic support in the treatment of low output cardiac failure associated with myocardial infarction, open heart surgery, cardiomyopathies, septic shock and cardiogenic shock.
5 mg/ml concentrate for solution for infusion can also increase or maintain cardiac output during positive end expiratory pressure (PEEP) ventilation. 5 mg/ml concentrate for solution for infusion may also be used for cardiac stress testing as an alternative to exercise in patients for whom routine exercise cannot be satisfactorily performed.
This use of dobutamine should only be undertaken in units which already perform exercise stress testing and all normal care and precautions required for such testing are also required when using dobutamine for this purpose. Paediatric population Dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Dobutamine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL015020054 · revised December 20, 2024
- [2]Health Canada (DPD) · 02242010 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.